First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis

Overview of attention for article published in Frontiers in endocrinology, January 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 12 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 35,898 followers.

RT @FrontEndocrinol: New Research: First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor…

30 Jan 2024

Reply Repost Favourite

RT @FrontEndocrinol: New Research: First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor…

29 Jan 2024

Reply Repost Favourite

New Research: First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis: Background The… https://t.co/pex6GXSTLm #

29 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.